PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced today the completion of a license agreement from Leiden University and the NIH for a patent which includes allosteric modulators to the A3 adenosine receptor. Can-Fite will pay license signing fee of €25,000 and annual minimal royalties of €10,000. In addition, the company will pay milestone payments up to €850,000 based on clinical development progress till marketing approval and royalty payments of 2-3% on net sales.
